Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Little is known about the support needed to improve compliance with Chantix for smoking cessation. This is a two arm pilot study of African American smokers to provide varying levels of side effect management and compliance support during a 12 week treatment period. The primary aim of the study is to estimate the effect of induction support compared to standard care in increasing compliance with Chantix at month 3

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nikki Nollen, PhD, MA
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• African American

• 18-75 years of age

• Smoke more than 10 cigarettes per day

• Have a functioning telephone number

• Be interested in quitting smoking

• Be willing to take 3 months of Chantix

• Be willing to complete all study visits

Exclusion Criteria:

• Renal impairment

• Evidence or history of clinically significant allergic reactions to Chantix

• Cardiovascular event in the past month

• History of alcohol or drug abuse/dependency in the past year

• Major depressive disorder in the last year requiring treatment

• History of panic disorder

• Psychosis, bipolar or eating disorder

• Use of antidepressants, antipsychotics, mood stabilizers/anticonvulsants or naltrexone

• Use of tobacco products other than cigarettes

• Use of nicotine replacement therapy, bupropion, clonidine or nortriptyline in the month prior to enrollment

• Prior use of Chantix

• Women who are pregnant, contemplating getting pregnant or breastfeeding

• Plans to move from Kansas City during the 3 month treatment phase

• Another household member enrolled in the study